Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or Stage II), or node-positive (Stage III) breast cancer to be treated with adjuvant endocrine therapy.
Prosigna Package Insert
to download the Prosigna Package Insert.
to view the Prosigna Material Safety Data Sheet.
Prosigna Product Data Sheet
Click here to download the Prosigna Product Data Sheet.
Click here to download the nCounter Dx Analysis System User Manual.